All Posts Tagged With: "TEVA"
(BMY) Company News for January 04, 2012 – Corporate Summary
• Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum Exploration & Production, a unit of China Petroleum...
8Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior...
27Dec2011 | vitalstocks | 0 comments | Continued(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator...
6Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Approved for Zinecard Generic
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of...
1Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic...
28Nov2011 | vitalstocks | 0 comments | Continued(AEM) Company News for November 4, 2011 – Corporate Summary
• Allos Therapeutics (NASDAQ:ALTH) posted a Q3 loss of $0.11 per share, lower than the Zacks Consensus Estimate for a loss of $0.15 per share. Revenues for the quarter rose 73.2% year-over-year to $14.2 million, surpassing the Zacks Consensus Estimate of $13.0 million • ...
4Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First...
2Nov2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Roche for Xeloda
Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which...
23Sep2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling
Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA)...
1Sep2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus...
25Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine...
18Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved...
27Jul2011 | vitalstocks | 0 comments | Continued(BHP) Company News for July 18, 2011 – Corporate Summary
• BHP Billiton Ltd. (NYSE:BHP) said it will be acquiring Petrohawk Energy Corporation (NYSE:HK) for $12.1 billion • Investor Carl Icahn offered to buy Clorox Corporation (NYSE:CLX) for $12.6 billion. Shareholders of Clorox are to get $76.50 per share in cash under...
18Jul2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access...
14Jul2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Downgraded to Neutral
We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00. Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable quality and efficacy as the national brands....
10Jul2011 | vitalstocks | 0 comments | Continued(MS) Merck KGaA Seeks Rebif Extension
Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is seeking approval for Rebif to treat patients who have experienced a single demyelinating...
7Jul2011 | vitalstocks | 0 comments | Continued(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis...
23Jun2011 | vitalstocks | 0 comments | Continued(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute
Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable...
22Jun2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Wins Favorable Ruling Against Teva Pharmaceutical Industries
Watson Pharmaceuticals Inc. (WPI) recently announced that the United States District Court for the District of Nevada denied Teva Pharmaceutical Industries Ltd.’s (TEVA) request for a preliminary injunction and a temporary restraining order to prevent Watson Pharma from launching...
21Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago...
27May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded...
27May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches Generic Drugs
MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and...
21May2011 | vitalstocks | 0 comments | Continued(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues...
18May2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Cruises Past Estimates – Lifts Outlook
Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues...
8May2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product...
5May2011 | vitalstocks | 0 comments | Continued(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations
Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76. First quarter revenues, which increased 24.9% to $745.1 million, missed the Zacks Consensus Estimate...
5May2011 | vitalstocks | 0 comments | Continued